Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Ranolazine Improves Right Ventricular Function in Patients With Precapillary Pulmonary Hypertension: Results From a Double-Blind, Randomized, Placebo-Controlled Trial

Journal of Cardiac Failure(2020)10.1016/j.cardfail.2020.10.006Source: DataRank Database

Ranolazine Improves Right Ventricular Function in Patients With Precapillary Pulmonary Hypertension: Results From a Double-Blind, Randomized, Placebo-Controlled Trial is a research paper published in Journal of Cardiac Failure (2020). On theSindex it has a DataRank of 0. It has been cited 44 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

44 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 2.96)OA: closedTopics (35)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Paul R. Forfia ORCID,Anjali Vaidya ORCID,Jeremy A. Mazurek ORCID,Myung H. Park ORCID,Gautam Ramani ORCID

Live enrichment

PubMed:33223140 OpenAlex:https://openalex.org/W3093934918

National Institutes of Health

Grant: HL 122596

National Institutes of Health

Grant: HL 138437

National Institutes of Health

Grant: R01 HL124021

National Institutes of Health

Grant: UH2 TR002073

American Heart Association

Grant: 18EIA33900027

United Therapeutics Corporation

Cardiovascular Medical Research and Education Fund

Pfizer

Actelion Pharmaceuticals

Gilead Sciences

FWCI

2.96

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

closedLicense: https://www.elsevier.com/legal/tdmrep-license

publisherhttps://api.elsevier.com/content/article/PII:S1071916420314822?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1071916420314822?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cardfail.2020.10.006

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33223140

Fields of Study

Pulmonary Hypertension Research and TreatmentsCardiac electrophysiology and arrhythmiasHeart Failure Treatment and ManagementHeart FailureHumansHypertension, PulmonaryQuality of LifeRanolazineStroke VolumeVentricular Dysfunction, RightVentricular Function, Right

MeSH Terms

RanolazineHeart FailureHumansHypertension, PulmonaryQuality of LifeStroke VolumeVentricular Function, RightVentricular Dysfunction, Right

Keywords

MedicineRanolazineCardiologyInternal medicinePlaceboEjection fractionNatriuretic peptideQuality of life (healthcare)Cardiac magnetic resonance imagingRandomized controlled trialAdverse effectHeart failureMagnetic resonance imagingRadiologyPulmonary hypertensionRight Ventricle

Ranolazine Improves Right Ventricular Function in Patients With Precapillary Pulmonary Hypertension: Results From a Double-Blind, Randomized, Placebo-Controlled Trial

FAIR Checklist

Authors (8)

Funding (10 grants)

Impact

Open Access

Topics